bloating nos; persistent asthenia; disorder equilibrium; dizziness; back ache; heavy menstrual bleeding / abundant menstrual flow; breast swelling; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the agency regulatory authority-web. regulatory number: it-minisal02-843549. a 49 year-old female patient received bnt162b2 (comirnaty), intramuscular, administration date 17dec2021 (lot number: fk6304) at the age of 49 years as dose 1, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: abdominal distension (medically significant) with onset 17dec2021, outcome "not recovered", described as "bloating nos"; asthenia (medically significant) with onset 17dec2021, outcome "not recovered", described as "persistent asthenia"; balance disorder (medically significant) with onset 17dec2021, outcome "not recovered", described as "disorder equilibrium"; dizziness (medically significant) with onset 17dec2021, outcome "not recovered", described as "dizziness"; back pain (medically significant) with onset 17dec2021, outcome "not recovered", described as "back ache"; heavy menstrual bleeding (medically significant) with onset 17dec2021, outcome "not recovered", described as "heavy menstrual bleeding / abundant menstrual flow"; breast swelling (non-serious) with onset 17dec2021, outcome "not recovered", described as "breast swelling". no follow-up attempts are possible. no further information is expected.; sender's comments: linked report(s) : it-pfizer inc-202200307311 same patient / drug, different dose / events;it-pfizer inc-202200307311 same patient / drug, different dose / events